US3152180A
(en)
|
1960-08-25 |
1964-10-06 |
Studiengesellschaft Kohle Mbh |
Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
|
US3391142A
(en)
|
1966-02-09 |
1968-07-02 |
Lilly Co Eli |
Adamantyl secondary amines
|
GB1175820A
(en)
|
1966-02-18 |
1969-12-23 |
Upjohn Co |
Amino-Adamantane Derivatives
|
ES413944A1
(es)
|
1972-04-20 |
1976-06-01 |
Merz & Co |
Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
US4284444A
(en)
|
1977-08-01 |
1981-08-18 |
Herculite Protective Fabrics Corporation |
Activated polymer materials and process for making same
|
US4148896A
(en)
|
1978-02-22 |
1979-04-10 |
E. I. Du Pont De Nemours And Company |
Antidepressant combination
|
DE2856393C2
(de)
|
1978-12-27 |
1983-04-28 |
Merz + Co GmbH & Co, 6000 Frankfurt |
Arzneimittel zur Behandlung von Morbus Parkinson
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4346112A
(en)
|
1981-06-29 |
1982-08-24 |
University Patents Inc. |
Composition and method for treating patients having Parkinson's Disease
|
JPS584718A
(ja)
|
1981-06-30 |
1983-01-11 |
Nippon Chibagaigii Kk |
新規適応症に用うる医薬製剤
|
DK150008C
(da)
|
1981-11-20 |
1987-05-25 |
Benzon As Alfred |
Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
|
US5366738A
(en)
|
1982-07-29 |
1994-11-22 |
Merck & Co., Inc. |
Controlled release drug dispersion delivery device
|
WO1986000814A1
(en)
|
1984-07-24 |
1986-02-13 |
Key Pharmaceuticals, Inc. |
Adhesive transdermal dosage layer
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
IT1188212B
(it)
|
1985-12-20 |
1988-01-07 |
Paolo Colombo |
Sistema per il rilascio a velocita' controllata di sostanze attive
|
ES2029805T3
(es)
|
1986-04-16 |
1992-10-01 |
Asta Pharma Aktiengesellschaft |
Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.
|
GB8613689D0
(en)
*
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
GB8807504D0
(en)
|
1988-03-29 |
1988-05-05 |
Sandoz Ltd |
Improvements in/relating to organic compounds
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
US5330766A
(en)
*
|
1989-01-06 |
1994-07-19 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
US5202128A
(en)
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
US5334618A
(en)
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
ATE94384T1
(de)
|
1989-04-14 |
1993-10-15 |
Merz & Co Gmbh & Co |
Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
WO1991006291A1
(en)
|
1989-10-26 |
1991-05-16 |
Nippon Shinyaku Co., Ltd. |
Sustained release preparation
|
IT1237904B
(it)
|
1989-12-14 |
1993-06-18 |
Ubaldo Conte |
Compresse a rilascio a velocita' controllata delle sostanze attive
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5221536A
(en)
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
US5057321A
(en)
*
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
GB9104854D0
(en)
|
1991-03-07 |
1991-04-17 |
Reckitt & Colmann Prod Ltd |
Sustained release compositions
|
US5614560A
(en)
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
KR100221695B1
(ko)
|
1991-08-12 |
1999-09-15 |
그린 마틴, 브라이언 쥐 테슬리 |
약학적 구상 제형
|
DE4225730C2
(de)
|
1992-08-04 |
2003-04-30 |
Merz Pharma Gmbh & Co Kgaa |
Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
|
US5358721A
(en)
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
JPH09500645A
(ja)
|
1993-07-22 |
1997-01-21 |
ワーナー−ランバート・コンパニー |
制御放出タクリン薬物送達システムおよびその製造方法
|
CA2176712C
(en)
|
1993-11-16 |
2000-05-23 |
Mantripragada Sankaram |
Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
|
US5395626A
(en)
*
|
1994-03-23 |
1995-03-07 |
Ortho Pharmaceutical Corporation |
Multilayered controlled release pharmaceutical dosage form
|
DE4413350A1
(de)
|
1994-04-18 |
1995-10-19 |
Basf Ag |
Retard-Matrixpellets und Verfahren zu ihrer Herstellung
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
US20020006438A1
(en)
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5677349A
(en)
|
1995-04-27 |
1997-10-14 |
Gilad; Gad M. |
Agmatine for the treatment of neurotrauma and neurodegenerative diseases
|
DE19528388A1
(de)
|
1995-08-02 |
1997-02-06 |
Hans Peter Prof Dr Med Zenner |
Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
|
AUPN605795A0
(en)
|
1995-10-19 |
1995-11-09 |
F.H. Faulding & Co. Limited |
Analgesic pharmaceutical composition
|
US6395292B2
(en)
|
1996-02-02 |
2002-05-28 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
WO1997045091A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Euro-Celtique, S.A. |
Sustained release oxycodone formulations with no fed/fast effect
|
CA2264182A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Algos Pharmaceutical Corporation |
Anticonvulsant containing composition for treating neuropathic pain
|
US5891885A
(en)
*
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
US5919826A
(en)
*
|
1996-10-24 |
1999-07-06 |
Algos Pharmaceutical Corporation |
Method of alleviating pain
|
JP4863534B2
(ja)
*
|
1996-10-25 |
2012-01-25 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
可溶形態浸透用量送達システム
|
DE19644998C1
(de)
|
1996-10-30 |
1998-06-10 |
Hanns Prof Dr Ludwig |
Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
JPH10203966A
(ja)
|
1996-11-21 |
1998-08-04 |
Takeda Chem Ind Ltd |
徐放性マイクロカプセルおよびその製造法
|
USRE39744E1
(en)
|
1997-03-11 |
2007-07-24 |
Daicel Chemical Industries, Ltd. |
Adamantane derivatives and process for producing them
|
US5849800A
(en)
*
|
1997-03-28 |
1998-12-15 |
The Penn State Research Foundation |
Use of amantadine for treatment of Hepatitis C
|
ATE219044T1
(de)
|
1997-04-10 |
2002-06-15 |
Pfizer |
Fluorosubstituierte adamantan-derivate
|
MY125849A
(en)
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
MA26553A1
(fr)
|
1997-10-17 |
2004-12-20 |
Centaur Pharmaceuticals Inc |
Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
|
FR2772615B1
(fr)
|
1997-12-23 |
2002-06-14 |
Lipha |
Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
|
US6251430B1
(en)
*
|
1998-02-04 |
2001-06-26 |
Guohua Zhang |
Water insoluble polymer based sustained release formulation
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
PE20000728A1
(es)
|
1998-06-26 |
2000-08-21 |
Cocensys Inc |
Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
|
ATE260642T1
(de)
|
1998-12-17 |
2004-03-15 |
Alza Corp |
Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
|
WO2000044353A1
(de)
|
1999-01-29 |
2000-08-03 |
Losan Pharma Gmbh |
Pharmazeutische zusammensetzungen
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
ATE285810T1
(de)
|
1999-03-03 |
2005-01-15 |
Optinose As |
Nasales verabreichungsgerät
|
SE9901077D0
(sv)
|
1999-03-23 |
1999-03-23 |
Astra Ab |
Novel use
|
US6183770B1
(en)
|
1999-04-15 |
2001-02-06 |
Acutek International |
Carrier patch for the delivery of agents to the skin
|
US6743211B1
(en)
|
1999-11-23 |
2004-06-01 |
Georgia Tech Research Corporation |
Devices and methods for enhanced microneedle penetration of biological barriers
|
WO2001019901A2
(en)
|
1999-09-14 |
2001-03-22 |
Smithkline Beecham Corporation |
Process for making aqueous coated beadlets
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
ATE292453T1
(de)
*
|
1999-12-09 |
2005-04-15 |
Alza Corp |
Antivirale arznei
|
WO2001046291A1
(en)
|
1999-12-22 |
2001-06-28 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
US6753011B2
(en)
|
2000-01-14 |
2004-06-22 |
Osmotica Corp |
Combined diffusion/osmotic pumping drug delivery system
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
US6455066B1
(en)
|
2000-03-10 |
2002-09-24 |
Epicept Corporation |
Intradermal-penetration agents for topical local anesthetic administration
|
US20040122090A1
(en)
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
JP2004515477A
(ja)
|
2000-12-07 |
2004-05-27 |
ニューロモレキュラー インコーポレイテッド |
Nmdaレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
|
CN1499960A
(zh)
|
2001-03-13 |
2004-05-26 |
����˹��ҩ�﹫˾ |
时间治疗剂型
|
US20060198815A1
(en)
|
2001-03-19 |
2006-09-07 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained release
|
CA2442798A1
(en)
|
2001-04-02 |
2002-10-10 |
Panorama Research, Inc. |
Antioxidant nitroxides and nitrones as therapeutic agents
|
DE10129265A1
(de)
|
2001-06-18 |
2003-01-02 |
Hf Arzneimittelforsch Gmbh |
Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
|
US20030045577A1
(en)
*
|
2001-08-15 |
2003-03-06 |
Madhat Maher N. |
Method for preventing infectious respiratory diseases
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030118647A1
(en)
*
|
2001-12-04 |
2003-06-26 |
Pawan Seth |
Extended release tablet of metformin
|
US20050271708A1
(en)
|
2002-03-05 |
2005-12-08 |
Thombre Avinash G |
Palatable controlled-release formulation for companion animals
|
ES2399880T3
(es)
|
2002-03-15 |
2013-04-04 |
Cypress Bioscience, Inc. |
Milnaciprán para el tratamiento del síndrome del intestino irritable
|
DE60322371D1
(de)
|
2002-03-29 |
2008-09-04 |
Alza Corp |
Volumensparende arzneiform zur kontrollierten freisetzung
|
AU2003298514A1
(en)
|
2002-05-17 |
2004-05-04 |
Eisai Co., Ltd. |
Methods and compositions using cholinesterase inhibitors
|
US20040102525A1
(en)
|
2002-05-22 |
2004-05-27 |
Kozachuk Walter E. |
Compositions and methods of treating neurological disease and providing neuroprotection
|
IL165255A0
(en)
|
2002-05-31 |
2005-12-18 |
Lundbeck & Co As H |
A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
|
DE10224170A1
(de)
|
2002-05-31 |
2003-12-11 |
Desitin Arzneimittel Gmbh |
Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
|
US6945952B2
(en)
|
2002-06-25 |
2005-09-20 |
Theraject, Inc. |
Solid solution perforator for drug delivery and other applications
|
MXPA05000224A
(es)
|
2002-06-26 |
2005-06-03 |
Alza Corp |
Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
CA2493301A1
(en)
|
2002-07-29 |
2004-02-12 |
Glaxo Group Limited |
Sustained release formulations comprising lamotrigine
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
DE10237082B4
(de)
*
|
2002-08-09 |
2014-12-31 |
Sartorius Stedim Biotech Gmbh |
Verfahren und Vorrichtung zur biotechnologischen Herstellung von Wertstoffen
|
CA2500662A1
(en)
|
2002-10-03 |
2004-04-15 |
Cypress Bioscience, Inc. |
Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
|
GEP20094759B
(en)
|
2002-10-24 |
2009-08-25 |
Merz Pharma Gmbh & Co Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
US20060024366A1
(en)
|
2002-10-25 |
2006-02-02 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
US20040121010A1
(en)
*
|
2002-10-25 |
2004-06-24 |
Collegium Pharmaceutical, Inc. |
Pulsatile release compositions of milnacipran
|
US20040097484A1
(en)
|
2002-11-14 |
2004-05-20 |
Marc Cantillion |
Once a day galantamine pharmaceutical compositions and methods of use
|
US20100092562A1
(en)
|
2002-11-26 |
2010-04-15 |
Hollenbeck R Gary |
Sustained-release drug delivery compositions and methods
|
EP1572164A2
(en)
|
2002-12-18 |
2005-09-14 |
Pain Therapeutics, Inc. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
EP1595535A2
(en)
*
|
2002-12-23 |
2005-11-16 |
Osmotica Costa Rica Sociedad Anonima |
Delivery device containing venlafaxine and memantine and use method thereof
|
US20050031651A1
(en)
|
2002-12-24 |
2005-02-10 |
Francine Gervais |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
US20040185097A1
(en)
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
AR043467A1
(es)
|
2003-03-05 |
2005-07-27 |
Osmotica Argentina S A |
Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
|
US20050065219A1
(en)
|
2003-03-27 |
2005-03-24 |
Lipton Stuart A. |
Treatment of demyelinating conditions
|
EP1638931A4
(en)
|
2003-06-11 |
2007-11-07 |
Neuromolecular Inc |
METHOD FOR TARGETING A THERAPEUTIC AGENT
|
KR20060033727A
(ko)
|
2003-06-16 |
2006-04-19 |
알러간, 인코포레이티드 |
메만틴 경구 투여 제형
|
JP2007519608A
(ja)
|
2003-09-19 |
2007-07-19 |
ペンウェスト ファーマシューティカルズ カンパニー |
時間治療用剤形
|
JP2007505921A
(ja)
|
2003-09-19 |
2007-03-15 |
ペンウェスト ファーマシューティカルズ カンパニー |
遅延放出剤形
|
US20080026081A1
(en)
|
2003-11-21 |
2008-01-31 |
Axel Unterbeck |
Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
|
US20050119249A1
(en)
|
2003-12-02 |
2005-06-02 |
Erik Buntinx |
Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
US20050232990A1
(en)
|
2003-12-31 |
2005-10-20 |
Garth Boehm |
Donepezil formulations
|
WO2005065661A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Immediate, controlled and sustained release formulations of galanthamine
|
WO2005072125A2
(en)
|
2004-01-16 |
2005-08-11 |
Massachusetts Institute Of Technology |
Composite materials for controlled release of water soluble products
|
WO2005072705A1
(en)
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
EP1734920A2
(en)
*
|
2004-02-13 |
2006-12-27 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
|
CA2556214A1
(en)
*
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
DK1742624T3
(da)
*
|
2004-02-18 |
2010-03-08 |
Sepracor Inc |
Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
|
MXPA06014587A
(es)
*
|
2004-06-17 |
2007-04-27 |
Forest Laboratories |
Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
|
EP1765305A4
(en)
|
2004-07-09 |
2008-06-04 |
Drugtech Corp |
REGULATED PHASE COMPOSITION TECHNOLOGY USED AS ENHANCED MEDICATION PROTECTION METHOD
|
US8609198B2
(en)
*
|
2004-07-21 |
2013-12-17 |
Hewlett-Packard Development Company, L.P. |
Pharmaceutical dose form with a patterned coating and method of making the same
|
WO2006024018A2
(en)
*
|
2004-08-24 |
2006-03-02 |
Neuromolecular Pharmaceuticals, Inc. |
Compositions for treating nociceptive pain
|
EP1799264A2
(en)
*
|
2004-10-08 |
2007-06-27 |
Neuromolecular Pharmaceuticals Inc |
Methods and compositions for treating migraine pain
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
JP2008520736A
(ja)
|
2004-11-23 |
2008-06-19 |
アマダス ファーマシューティカルズ インコーポレイテッド |
持続放出コーティングまたはマトリックスおよびnmda受容体アンタゴニストを含む組成物、そのようなnmdaアンタゴニストの被験体への投与方法
|
EP2623099A1
(en)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
US8574626B2
(en)
*
|
2004-12-03 |
2013-11-05 |
Osmotica Kereskedelmi és Szolgáltató KFT |
Osmotic device containing amantadine and an osmotic salt
|
US8252331B2
(en)
*
|
2004-12-03 |
2012-08-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Osmotic device containing amantadine and an osmotic salt
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
US20090208579A1
(en)
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
US20070036843A1
(en)
|
2005-01-28 |
2007-02-15 |
Collegium Pharmaceutical, Inc. |
Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
|
US20080279819A1
(en)
*
|
2005-02-15 |
2008-11-13 |
Adamas Pharmaceuticals, Inc. |
Combinations Therapy for Treatment of Demyelinating Conditions
|
KR101406456B1
(ko)
|
2005-04-06 |
2014-06-20 |
아다마스 파마슈티칼스, 인코포레이티드 |
Cns 장애의 치료를 위한 방법 및 조성물
|
US20060280795A1
(en)
|
2005-06-08 |
2006-12-14 |
Dexcel Pharma Technologies, Ltd. |
Specific time-delayed burst profile delivery system
|
WO2007036952A2
(en)
|
2005-07-01 |
2007-04-05 |
Rubicon Research Pvt Ltd. |
Novel sustained release dosage form
|
US7951760B2
(en)
*
|
2005-07-29 |
2011-05-31 |
Chevron Oronite S.A. |
Overbased alkali metal alkylhydroxybenzoates having low crude sediment
|
US20080248107A1
(en)
|
2005-08-24 |
2008-10-09 |
Rubicon Research Pvt. Ltd. |
Controlled Release Formulation
|
US20070104778A1
(en)
|
2005-11-07 |
2007-05-10 |
Hongxia Zeng |
Controlled-release emulsion compositions
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
WO2007136737A1
(en)
|
2006-05-19 |
2007-11-29 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of viral infections
|
US20080089861A1
(en)
*
|
2006-07-10 |
2008-04-17 |
Went Gregory T |
Combination therapy for treatment of demyelinating conditions
|
ATE510538T1
(de)
*
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
CA2662123C
(en)
|
2006-08-30 |
2015-12-01 |
Jagotec Ag |
Controlled release oral dosage formulations comprising a core and one or more barrier layers
|
EP1961414A1
(en)
|
2007-02-21 |
2008-08-27 |
FUJIFILM Manufacturing Europe B.V. |
A controlled release composition comprising a recombinant gelatin
|
US7981930B2
(en)
|
2007-03-13 |
2011-07-19 |
Adamas Pharmaceuticals, Inc. |
Compositions and kits for treating influenza
|
JP2010523587A
(ja)
*
|
2007-04-02 |
2010-07-15 |
パーキンソンズ インスティテュート |
治療処置の副作用の低減のための方法および組成物
|
EP2150239A1
(en)
|
2007-04-24 |
2010-02-10 |
Boehringer Ingelheim International GmbH |
Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
|
EP1987815A1
(en)
*
|
2007-05-04 |
2008-11-05 |
Schwarz Pharma Ag |
Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
|
US8313770B2
(en)
|
2007-05-30 |
2012-11-20 |
Neos Therapeutics, Lp |
Modifying drug release in suspensions of ionic resin systems
|
AU2008258596B2
(en)
|
2007-06-04 |
2013-02-14 |
Egalet Ltd |
Controlled release pharmaceutical compositions for prolonged effect
|
US8637080B2
(en)
|
2007-06-28 |
2014-01-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Rupturing controlled release device comprising a subcoat
|
US20090041820A1
(en)
|
2007-08-07 |
2009-02-12 |
Wu Margaret M |
Functional polymer compositions
|
CN101801356B
(zh)
|
2007-09-21 |
2016-10-19 |
赢创罗姆有限公司 |
耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
|
CN102014883A
(zh)
|
2008-01-31 |
2011-04-13 |
麦克内尔-Ppc股份有限公司 |
具有调释型活性成分的可食用膜条片
|
JP2010040238A
(ja)
*
|
2008-08-01 |
2010-02-18 |
Panasonic Corp |
プラズマディスプレイパネルの製造方法
|
WO2010017821A1
(en)
|
2008-08-14 |
2010-02-18 |
Daniel Bar-Shalom |
Coated tablets with a remaining degradation surface over the time8
|
US20100159001A1
(en)
|
2008-12-19 |
2010-06-24 |
Cardinal John R |
Extended-Release Pharmaceutical Formulations
|
US20100221328A1
(en)
*
|
2008-12-31 |
2010-09-02 |
Wertz Christian F |
Sustained-release formulations
|
US20130059008A1
(en)
|
2009-01-23 |
2013-03-07 |
Jeffrey L. Atkinson |
Drying methods for tuning microparticle properties
|
CA2755808C
(en)
|
2009-03-18 |
2016-01-19 |
Evonik Roehm Gmbh |
Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
|
WO2010111232A2
(en)
|
2009-03-23 |
2010-09-30 |
Micell Technologies, Inc. |
Drug delivery medical device
|
EP2413898A1
(en)
|
2009-04-03 |
2012-02-08 |
Coating Place, Inc. |
Modified-release pharmaceutical drug composition
|
BR112012013487A2
(pt)
|
2009-12-02 |
2017-10-03 |
Adamas Pharmaceuticals Inc |
Composições de amantadina e métodos de uso
|
GB201003766D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Pulsatile drug release
|
EP2706641A1
(en)
|
2012-09-05 |
2014-03-12 |
Siemens Aktiengesellschaft |
Method to provide primary control power by an energy storage system
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
CN117860718A
(zh)
|
2017-08-24 |
2024-04-12 |
阿达玛斯药物有限责任公司 |
金刚烷胺组合物、其制备和使用方法
|